Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update.
A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study.
GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40mg three-times weekly versus 20mg daily in patients with relapsing-remitting multiple sclerosis.
Focused suggestion with somatic anchoring technique: rapid self-hypnosis for pain management.
The effect of Nintendo(R) Wii(R) on balance in people with multiple sclerosis: a pilot randomized control study.
Immune reconstitution inflammatory syndrome in a patient treated with natalizumab presenting progressive multifocal leukoencephalopathy.
The investigation of acute optic neuritis: a review and proposed protocol.
An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™ (PERSIST)
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Phase IV Study Reports Multiple Sclerosis Success with Teriflunomide
Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
Santhera receives first product approval: Health Canada approves Catena® for treatment of Friedreich's ataxia
Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation.
Exogenous schwann cells migrate, remyelinate and promote clinical recovery in experimental auto-immune encephalomyelitis.
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
Connective Tissue and its Growth Factor, CTGF, Distinguish the Morphometric and Molecular Remodeling of the Bladder in a Model of Neurogenic Bladder.
Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis.
Imaging Microglial/Macrophage Activation in Spinal Cords of Experimental Autoimmune Encephalomyelitis Rats by Positron Emission Tomography Using the Mitochondrial 18 kDa Translocator Protein Radioligand [18F]DPA-714.
Transcriptomics: mRNA and alternative splicing.
Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis.

Pages